[go: up one dir, main page]

WO2003092619A3 - Prevention and treatment of type 2 diabetes - Google Patents

Prevention and treatment of type 2 diabetes Download PDF

Info

Publication number
WO2003092619A3
WO2003092619A3 PCT/US2003/013820 US0313820W WO03092619A3 WO 2003092619 A3 WO2003092619 A3 WO 2003092619A3 US 0313820 W US0313820 W US 0313820W WO 03092619 A3 WO03092619 A3 WO 03092619A3
Authority
WO
WIPO (PCT)
Prior art keywords
protofibrils
diabetes
methods
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/013820
Other languages
French (fr)
Other versions
WO2003092619A2 (en
Inventor
George Rainer Siber
Subramonia Padmanabha Pillai
Philip David Fernsten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Wyeth LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Priority to AU2003231279A priority Critical patent/AU2003231279A1/en
Publication of WO2003092619A2 publication Critical patent/WO2003092619A2/en
Publication of WO2003092619A3 publication Critical patent/WO2003092619A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and compositions are provided to prevent or treat Type 2 diabetes. Such methods entail administering an agent that induces in the patient a beneficial immune response against islet amyloid fibrils, protofibrils and/or amyloid plaque deposited in the islets of the human pancreas. In such methods, a suitable agent is an antigen that is surface-exposed only in islet amyloid fibrils, protofibrils, protofibrils and/or amyloid plaque but not in soluble, native islet amyloid polypeptide (IAPP), or an antibody thereto.
PCT/US2003/013820 2002-04-30 2003-04-30 Prevention and treatment of type 2 diabetes Ceased WO2003092619A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003231279A AU2003231279A1 (en) 2002-04-30 2003-04-30 Prevention and treatment of type 2 diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37661802P 2002-04-30 2002-04-30
US60/376,618 2002-04-30

Publications (2)

Publication Number Publication Date
WO2003092619A2 WO2003092619A2 (en) 2003-11-13
WO2003092619A3 true WO2003092619A3 (en) 2004-10-07

Family

ID=29401377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013820 Ceased WO2003092619A2 (en) 2002-04-30 2003-04-30 Prevention and treatment of type 2 diabetes

Country Status (2)

Country Link
AU (1) AU2003231279A1 (en)
WO (1) WO2003092619A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227403B2 (en) 2003-12-17 2012-07-24 Wyeth Llc A-β immunogenic peptide carrier conjugates and methods of producing same
CN103037891A (en) * 2010-06-03 2013-04-10 雷蒙特亚特特拉维夫大学有限公司 Methods of treating diabetes and compositions capable of same
WO2014041069A1 (en) * 2012-09-12 2014-03-20 Neurimmune Holding Ag Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
US20150191541A1 (en) * 2013-12-06 2015-07-09 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015136055A1 (en) * 2014-03-12 2015-09-17 Neurimmune Holding Ag Novel compounds capable of antagonizing islet amyloid polypeptide (iapp) induced beta-cell damage and impaired glucose tolerance

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAIKARAN E.T.A.S. ET AL: "Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology", BIOCHEMICA ET BIOPHYSICA ACTA, vol. 1537, 2001, pages 179 - 203, XP004324245 *
KAHN S.E. ET AL: "Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes", DIABETES, vol. 48, February 1999 (1999-02-01), pages 241 - 253, XP002979967 *
PORTE JR. D. AND KAHN S.E.: "Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms", DIABETES, vol. 50, February 2001 (2001-02-01), pages S160 - S163, XP002979968 *
VERCHERE C.B. ET AL: "Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide", PNAS, vol. 93, April 1996 (1996-04-01), pages 3492 - 3496, XP002979966 *

Also Published As

Publication number Publication date
AU2003231279A8 (en) 2003-11-17
AU2003231279A1 (en) 2003-11-17
WO2003092619A2 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
BG104060A (en) Diabetes treatment with thiazolyidindion and methformine
MY134906A (en) Prevention and treatment of amyloidogenic disease
DE69912434D1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNCTIONAL DYSPEPSY AND / OR THE IRRIDAL SYNDROME AND THE USE OF NEW SUBSTANCES IN THIS COMPOSITION
TR200100079T2 (en) Glucagon-like peptide-1, which increases the ß-cell response to glucose
CA2072624A1 (en) Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
TWI263503B (en) Composition comprising an antibody or a polypeptide preparation as the active agent for the prevention and treatment of amyloidogenic disease and method for in vitro screening of the antibody
DE58901401D1 (en) PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS.
PT1146896E (en) FORMULATIONS MONODISPERSAS OF ANILOGO ACILADO AND HEXAMERICO INSULINA
DE69430868D1 (en) METHODS AND PREPARATIONS FOR DELAYING OR PREVENTING AUTOIMMUNE DISEASES
RU2000100346A (en) METHODS FOR TREATING OBESITY
GB9408775D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
DE69033970D1 (en) HUPERZIN A ANALOGUE CONNECTIONS
UA42040C2 (en) Polypeptide, method for diagnostics of insulin-dependent diabetes mellitus (IDDM), which has been developed or is developing (variants), kit for diagnostics of (variants), preparation for prevention of treatment of IDDM, pharmaceutical composition for prophylaxis or treatment of IDDM
BG104091A (en) Cd154 blockade therapty in tissue transplantation of pancreatic isles
WO2003092619A3 (en) Prevention and treatment of type 2 diabetes
EP0937982A3 (en) Diagnostic and therapeutic agent for treatment of autoimmune hepatitis
IL107153A (en) Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
FI955837A0 (en) A process for preparing an oral solid dosage form containing diclofenac
IL111196A0 (en) Peptides and pharmaceutical compositions comprising them
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
MD950010A (en) Composition for removing or deactivation of toxic components from blood and other extracellular body liquids and methol for prepations theref
ZA972232B (en) A method of prophylaxis and/or treatment.
UA42351A (en) Method for treating tuberculosis
WO2000062805A8 (en) A method of reversing thymic atrophy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP